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Ion channels regulate a broad range of cellular activities. Alteration in ion channel function has been reported in different human
pathologies, such as cardiac, neuromuscular, autoimmune diseases, and cancer. We investigated the expression of hERG1 Kþ
channels in the human upper gastrointestinal tract, focusing our attention on the lower esophagus. In particular, we analyzed by
both Reverse transcription and polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) endoscopic samples
obtained from normal subjects, from patients suffering from gastroesophageal reflux, associated or not with esophagitis, and from
patients affected by Barrett’s esophagus (BE), that is, intestinalmetaplasia. None of the normal samples, nor those frompatients with
gastro-esophageal reflux symptoms and reflux esophagitis expressed the hERG1protein.On the other hand, 69%of patientswith BE
expressed hERG1. Since BE is a preneoplastic lesion, dysplasias (Ds) and adenocarcinomas (ADKs) arising on a previously
diagnosed BE were also analyzed, and all the samples showed a high expression of the hERG1 protein. The surveillance of patients
with BE showed that 89% of those who later developed ADKs displayed hERG1 expression. Data here reported, support the
hypothesis that hERG1 expression marks an early step of the progression of normality to cancer in the human esophagus through a
metaplastic and dysplastic stage. J. Cell. Physiol. 209: 398–404, 2006.  2006 Wiley-Liss, Inc.
Increasing evidence has recently addressed an altered
expression of ion channel encoding genes, as well as ion
channels malfunction as an important step in the
development and progression of several human dis-
eases, from cardiac, neuromuscular, and autoimmune
diseases to cancers (Ashcroft, 2000). The role of ion
channels in pathophysiological processes is as diverse
as the ion channels themselves, ranging from the regu-
lation of cellular excitability and secretion to the
control of cell proliferation and survival (Arcangeli and
Becchetti, 2005). Potassium channels encoded by the
human ether-a-go-go related gene 1 (herg1) (hERG1
channels) are involved in several human diseases,
from arrhythmias (Sanguinetti and Tristani-Firouzi,
2006), to hyperthension (Sarzani et al., 2006). Moreover,
we have repeatedly reported that the mis- and over-
expression of hERG1 channels occurs in many types
of human cancers (Arcangeli, 2005). No indications
have been gathered so far regarding the expression of
hERG1 channels in inflammatory and preneoplastic
conditions.
We, therefore, designed a study to investigate the
expression of hERG1 channels in pathologic conditions
of the human upper gastrointestinal tract, with parti-
cular attention to esophageal diseases like the gastro-
esophageal reflux disease (GERD) and the so called
Barrett’s esophagus (BE). BE is an acquired condition
that results from GERD and is characterized by the
metaplastic replacement of the normal squamous
epithelium of the lower esophagus, up to the squamoco-
lumnar junction (also known as Z line), by a columnar,
intestinal-like, epithelium (Spechler, 2002). In other
words, when defence mechanisms in esophageal mucosa
are chronically overwhelmed by harmful agents, BE
develops as a healing process protecting the esophagus
from further damage (Guillem, 2005). BE is a premalig-
nant condition that predisposes to the development
of esophageal adenocarcinoma (Haggitt and Dean,
1985), atumor with an increasing frequency in most
western countries (Newnham et al., 2003). Esophageal
adenocarcinomas (ADKs) may develop from BE through
a multistep morphological pathway (Fle´jou, 2005). This
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process is characterized by increasing grades of dyspla-
sia (D) (intraepithelial neoplasia) that precede the onset
of an invasive adenocarcinoma (Montgomery et al.,
2001) and are paralleled by the accumulation of genetic
abnormalities (Jankowski et al., 1999; Merola et al.,
2006). Among these genetic changes, mutation of the
human suppressor gene p53 have been reported to
characterize BE, and have been, therefore, proposed as
an adjunct to morphology for the screening and
surveillance of patients with BE (Merola et al., 2006).
We studied the expression of the herg1 gene and of the
hERG1 protein in endoscopic samples obtained from
patients suffering from BE. Such expression was
compared with that occurring in samples of normal
esophageal mucosa, as well as of mucosa from patients
with symptoms of GERD with or without histologically
confirmed esophagitis (E). All the endoscopic samples
were taken from the lower esophagus, below the
squamocolumnar junction; that is, the areas where the
intestinal metaplasia characterizing BE arises. Finally,
the expression of the hERG1 protein was evaluated
on samples of Ds and ADKs arising from a previously
diagnosed BE.
MATERIALS AND METHODS
Patients
Ninety patients (45 males and 45 females; mean age 55.8,
range 29–86) were enrolled in the study. All the patients
underwent endoscopic examinations due to gastroesophageal
reflux disease (GERD) symptoms and/or previous BE diag-
nosis, based on endoscopic and histological features. Patients
were treated at the Patologia Chirurgica 1 of the University of
Florence and the I Divisione Clinicizzata di Chirurgia
Generale of the University of Verona. In each patient, three
adjacent samples were taken immediately below the squamo-
columnar junction during the endoscopic examination by
means of grasp forceps. One was immediately frozen for RNA
extraction and the other two were fixed in 4% formaldehyde in
PBS to be embedded in paraffin for immunohistochemistry
(IHC) and for conventional histology, respectively. In all the
patients, an additional biopsy above the squamocolumnar
junction was taken to assess the presence or the absence of the
pathologic features of reflux E (hyperplasia of squamous
epithelium, papillary vascular ectasia, presence of inflamma-
tory cells). Histological diagnoses were assessed by LM
(Florence) and AT (Verona), respectively through conventional
techniques such as Hematoxylin-Eosin staining and Alcian
Blue Ph 2.5-PAS. Two groups were distinguished on the basis
of the histopathologic findings in the biopsy specimen which
was collected above the squamocolumnar junction: no histolo-
gic lesions (31 specimens from patients with GERD symptoms
but no histologic E, addressed as GERD) and E (40 specimens
from patients with both symptoms and histologic reflux E,
addressed as GERD plus E). This type of biopsy was also
collected in the patients belonging to the BE group (13 speci-
mens), and analyzed as above; however, such biopsy had no
relevance to the definition of the group, which was identified
on the basis of the currently accepted criterion of the presence
of intestinal metaplasia in the biopsy collected below the
squamocolumnar junction and above the gastroesophageal
junction. Finally, endoscopic samples were collected from six
patients without reflux symptoms undergoing upper endo-
scopy for different reasons (two gastric leiomiomas, three
peptic ulcers, one gastritis). Also in this case, biopsies were
collected both above and below the squamocolumnar junction,
and the above methodological criteria were applied. These
specimens did not show any histologic lesion in the esophageal
biopsies either above or below the squamocolumnar junction
and were, therefore, considered as controls for the purpose of
the study, and addressed as ‘‘normal esophagus’’ (N).
A retrospective immunohistochemical analysis was per-
formed on 6 BE-associated Ds and 8 BE-derived esophageal
ADKs, as well as on 27 cases of BE for which a 5-year follow-up
was available, and were, therefore, differentiated as non
progressing, or progressing to a pure adenocarcinoma. Finally,
archival specimens of two patients where the Barrett’s
esophagus-dysplasia-adenocarcinoma sequence was followed,
were analyzed.
Reverse transcription (RT) and polymerase
CHAIN reaction (PCR)
Total RNA was extracted as previously reported (Cherubini
et al., 2000). Briefly, all the samples were homogenized in a
Guanidine Thyocianate solution and total RNA was extracted
using Phenol and Chloroform-Isoamylic alcohol standard
protocol. RNA (2 mg) was then retrotranscribed as previously
described (Pillozzi et al., 2002) using 200 U of Superscript II
Reverse Trascriptase (Invitrogen, Milan, Italy) and random
hexamers (2.5 mM) in a 20 ml reaction, according to the
manufacturer’s protocol.
cDNA (1 ml) was then amplified by PCR in a 50 ml reaction
using Platinum PCR Supermix (Invitrogen) and the following
primers (Cherubini et al., 2000) at a concentration of 100 ng/ml:
herg1 forward: 50-TCCAGCGGCTGTACTCGGGC-30.
herg1 reverse: 50-TGGACCAGAAGTGGTCGGAGAACTC-30.
gapdh forward: 50-AACAGCCTCAAGATCATCAGCAA-30.
gapdh reverse: 50-CAGTCTGGGTGGCAGTGAT-30.
The conditions for the amplification of herg1 and gapdh
genes were the same reported by Pillozzi et al. (2002): 2 min at
948C, followed by 35 cycles composed of a denaturation step at
948C for 30 sec, an annealing step at 568C (herg1) or 608C
(gapdh) for 1 min, and an elongation step at 728C for 1 min. An
additional over-extension was then performed at 728C for
2 min.
On representative samples Real Time PCR experiments
using the TaqMan Gene Expression assay for human CD45 kit
(Applied Biosystems, Foster City, CA) were performed,
according to the manufacturer’s instructions.
Immunohistochemistry (IHC)
IHC was performed as previously reported (Lastraioli et al.,
2004) on 7-mm sections adhered on positive-charged micro-
scope slides. After dewaxing and re-hydrating, the specimens
were treated with a 1%H2O2 solution and antigen retrieval was
carried out using a Proteinase K (Roche, Milan, Italy) solution
(5 mg/ml in PBS). Permeabilization was performed with a 0.1%
Triton X100 in UltraVBlock (LabVision, Fremont, CA) solu-
tion. The anti-hERG1 polyclonal antibody (Alexis Corporation,
Lausen, Switzerland) was then applied and incubation was
carried out at 48C O/N. The antibody was diluted in UltraV-
Block (LabVision): PBS 1:10 (v/v) at a 1:200. When dealing with
bioptic or archival specimens, the antibody was diluted 1:200
and 1:500, respectively. In any case, preliminary experiments
were carried out to test the best concentration of the anti-
hERG1 antibody to be used, depending on the different
fixatives used. Detection was carried out using a commercially
available kit (PicTure Plus Kit, Zymed, Milan, Italy) as well as
DAB chromogen solution (Zymed), according to the manufac-
turer’s instructions. Every sample showing staining of more
than 1% epithelial cells was considered as positive while
samples negative for hERG1 staining in epithelial cells were
considered as negative irrespective of immunoreactivity in
non-epithelial (smooth muscle, inflammatory) cells.
An IHC using Mib-1 antibody specific for Ki-67 antigen
(DakoCytomation, Milan, Italy) was performed on representa-
tive specimens. Antigen retrieval was carried out with
microwave treatment in citrate buffer for 20 min; the primary
antibody was used at a 1:50 dilution and incubated at 258C for
1 h. Immunodetection was performed using EnVision kit
(DakoCytomation) followed by DAB chromogen solution
(DakoCytomation).
Evaluation of the results obtained through IHC experiments
was carried out by two independent operators.
Statistical analysis
The relationships between herg1 gene and hERG1 protein
expression and clinico-pathological parameters were evaluated
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through Fisher’s exact test. P-values < 0.05 were considered
statistically significant.
RESULTS
herg1 gene and hERG1 protein expression in
normal and pathological human esophagus
herg1 gene expression was analyzed by PCR on
90 endoscopic samples collected at the Patologia Chir-
urgica 1 of the University of Florence and the I Divisione
Clinicizzata of the University of Verona. Samples were
divided into four groups: (i) N without GERD symptoms;
(ii) GERD symptoms without histological esophagitis
(GERD); (iii) GERD symptoms with esophagitis (GERD
plus E); (iv) BE. All samples used for biomolecular and
immunohistochemical (see below) analysis were col-
lected below the squamocolumnar junction, that is, in
the anatomical region where the BE disease arises,
while the histopathological diagnosis of E and therefore,
the attribution of the patients to the groups of GERD and
GERD plus E was done on the biopsy sample collected
above the squamocolumnar junction. The gapdh house-
keeping gene was amplified as a control. Representative
gels are shown in Figure 1: none of the samples
belonging to N showed herg1 expression (part A, lanes
‘‘N’’). Similarly, no expression was detected in GERD
samples (part A, lanes ‘‘GERD’’). Examples of herg1
transcripts amplified from samples of patients with
GERD plus E are reported in part B; in this case, two out
of four samples showed a herg1-specific band. Finally,
examples of PCR amplification from BE samples are
shown in part C, where herg1 expression is evident in
all the samples reported in the figure. Overall, PCR
analysis showed that none of the normal samples and 6
out of 31 (20%) of GERD group expressed herg1. Among
GERD plus E samples, the herg1 transcript was
detected in 13 out of 40 samples (32%), while the
percentage of herg1-positive samples strongly increased
(69%) in BE samples.
Different cell types are present in the endoscopic
samples used for the PCR analysis; among them smooth
muscle cells, which highly express the erg1 gene in the
rat (Ohya et al., 2002), are represented. For this reason,
the PCR analysis was paralleled by an IHC analysis to
determine hERG1 protein expression at the histological
level in the epithelial cells. Representative light micro-
graphs of IHC analysis are reported in Figure 2 parts A–
D, whereas the quantitative IHC results concerning all
the samples are shown in Figure 3. No hERG1 expres-
sion was detected in normal samples either in the
lower cell layers of the squamous epithelium (Fig. 2 part
A) or in the cardiac-type epithelium present in samples
collected below the squamocolumnar junction (Fig. 2B).
Similar results were obtained in GERD samples.
Samples from patients with GERD plus E were negative
for hERG1 expression in epithelial cells, while an
evident staining in inflammatory cells infiltrating the
mucosa collected below the squamocolumnar junction
was evident (part C). The specificity of the immunoreac-
tion is more evident comparing this picture with that
relative to the negative control (inset to part C).
The same expression in inflammatory cells was also
detected in samples collected above the squamocolum-
nar junction (and used for the diagnosis of E) (not
shown). Conversely, samples from BE very often showed
Fig. 1. RT-PCR on esophageal biopsies. Amplification on herg1
(upper parts) and gapdh genes (lower parts) on: (A) normal esophagus
samples (N) and specimens deriving from patient with GERD (B)
biopsies of patients affected by esophagitis (GERD plus E); (C)
Barrett’s Esophagus samples (BE); FLG 29.1 cell line cDNA was used
as a positive control (C); St: 100 bp, New England Biolabs.
Fig. 2. Immunohistochemistry for the hERG1 protein on esophageal
biopsies. A: normal esophagus: squamous epithelium (taken above the
squamocolumnar junction); note that the upper portion of the
squamous epithelium shows an aspecific chromogen deposition in
dead keratinized cells. The inset shows the negative control (i.e., IHC
with no primary antibody in a different area of the same sample); (B)
normal esophagus: columnar epithelium (taken below the squamoco-
lumnar junction). The inset shows the negative control (i.e., IHC with
no primary antibody in a different area of the same sample); (C)
patient with esophagitis (note that the image here reported refer to
the sample taken below the squamocolumnar junction, while the
diagnosis of esophagitis was done on the sample taken above the
squamocolumnar junction, see Materials and Methods). The inset
shows the negative control (i.e., IHC with no primary antibody in a
different area of the same sample); (D) Barrett’s esophagus. The inset
shows the negative control (i.e., IHC with no primary antibody in a
different area of the same sample); (E) BE-derived dysplasia. The
inset shows the negative control (i.e., IHC with no primary antibody in
a different area of the same sample); (F) BE-derived adenocarcinoma.
The inset shows the negative control (i.e., IHC with no primary
antibody in a different area of the same sample); (G) Ki67 expression
in (1) esophagitis; (2) Barrett’s esophagus; (3) dysplasia; (4) Barrett’s
esophagus-derived esophageal adenocarcinoma.H: hERG1 expression
through the metaplasia-dysplasia-adenocarcinoma sequence: (1)
Barrett’s esophagus; (2) dysplasia; (3) Barrett’s esophagus-derived
esophageal adenocarcinoma. IHC was performed on 7-mm sections. As
described in Materials and Methods, the anti-hERG1 polyclonal
antibody (Alexis Corporation) was routinely used at a 1:200 dilution.
1:500 dilution was used for archival specimens. As concerning IHC for
Ki67, it was performed as described in Materials and Methods, with a
1:50 dilution. Bar: A 200 mm; B-H3 100 mm.
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an intense hERG1 immunostaining (part D). In parti-
cular, immunolabeling of hERG1 protein demonstrated
a strong chromogen deposition in metaplastic tissue;
in most samples, hERG1 expression was diffused
throughout the metaplastic glands, characterized by
the presence of goblet cells (as shown in Fig. 2D).
Alternatively, hERG1 positivity sometimes showed a
focal pattern (see arrow in part G1). In any case, all the
samples evaluated as ‘‘positive’’ showed an intense
staining in the cytoplasm of metaplastic cells with
respect to stromal cells (Fig. 2D). Here again, the
specificity of the immunoreaction is more evident
Fig. 2.
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comparing this picture with that of the negative control
(inset to part D). Results concerning IHC are summar-
ized in Figure 3: no hERG1 expression was shown in the
normal nor in the GERD group as well as in GERD plus
E samples. On the other hand, 69% of BE samples were
positive for hERG1 expression.
Overall, PCR and IHC results roughly overlapped in
esophageal tissue as previously reported in other
human normal and neoplastic tissues (Cherubini et al.,
2000; Lastraioli et al., 2004). Discrepancies were
observed in the groups of samples from patients with
GERD and GERD plus E. In this group, a higher
percentage of positive samples was detected by PCR
when compared to IHC (see Table 1). This discrepancy
would be due to the presence of either smooth muscle
cells (see Discussion) or inflammatory cells infiltrating
the tissue sample. This was confirmed by measuring
CD45 expression by quantitative Real Time PCR in
representative GERD plus E samples that resulted to be
either positive or negative for herg1 expression at the
PCR analysis. It emerged that CD45 expression (nor-
malized on the expression of the control gene, gapdh)
was significantly higher in GERD plus E samples that
were positive for herg1 expression (2.21 1.25 (n¼ 10)
versus 0.215 0.045 (n¼10);meanSE). This implies
that such samples are more contaminated by inflam-
matory cells. On the whole, our results have shown that
a high percentage of samples from patients affected by
BE express the hERG1 protein, with significant differ-
ences between BE and all the other groups (Table 1).
hERG1 expression along the
metaplasia-dysplasia-adenocarcinoma sequence
Since BE is thought to be the precursor lesion to
esophageal ADKs, we sought whether hERG1 expres-
sion might represent one of the earliest steps leading
esophageal epithelial cells to a cancerous state. There-
fore, we performed a retrospective IHC analysis on six
cases of Ds arising on a previously diagnosed Barrett’s
esophagus (BE-derived Ds) as well as on eight
pure ADKs arising from a previous BE (BE-derived
ADK). Representative examples of IHC performed on a
dysplastic and an adenocarcinoma sample are reported
in Figure 2, parts E and F, respectively. For comparison,
pictures of the negative controls are reported in the
insets. As previously reported for BE samples, hERG1
immunostaining was strong in the cytoplasm of neo-
plastic cells (Fig. 2F), while nuclei always turned out to
be negative, staining blue. As concerning Ds, a diffuse
pattern of expression was detected in the majority of
samples, while a focal pattern was observed only in some
of the samples (an example of which is reported in
Fig. 2E). In any case, an intense hERG1 immunostain-
ing of dysplastic cells with respect to the stroma was
observed. In ADKs, the pattern of hERG1 expression
was always of the diffuse type. Overall, the percentage of
hERG1-positive samples raised to 100% in BE-derived
Ds irrespective of the grade as well as in pure ADKs.
Four samples displayed mixed histological features with
both metaplastic and dysplastic areas; in these cases,
the hERG1 protein was expressed in both types of
lesions, with almost the same immunoreactivity. We
also assessed whether hERG1 immunoreactivity in our
samples overlapped with that of a proliferation-related
antigen. To this purpose BE, dysplastic, and ADK
samples were decorated with an anti-Ki67 antibody
(Mib-1). Results reported in parts G1–G4 clearly
showed that both GERD plus E (G1) and BE (G2)
samples were negative for Ki67 expression, while Ds
(G3) and ADKs (G4) were positive although with a
completely different staining pattern as compared to
that displayed by hERG1. In fact, Ki67 positivity in Ds
Fig. 3. hERG1 expression in various esophageal clinicopathological
situations. Histogram relative to IHC results. Data are expressed as
percentage of the total number of samples examined. N, normal
esophagus (n¼ 6); GERD, symptoms of gastroesophageal reflux
(n¼ 31); GERD plus E, symptoms of GERD with esophagitis
(n¼ 43); BE, Barrett’s esophagus (n¼ 21); D, Dysplasia (n¼ 6); ADK,
Adenocarcinoma (n¼9). White bars, hERG1 negative samples; Black
bars, hERG1 positive samples.
TABLE 1. Comparison between herg1 gene and hERG1 protein expression in different pathological conditions and statistical analysis in the
clinico-pathological groups
Positive
samples/total (%)
Normal
esophagus
(P-value)
GERD
(P-value)
GERD plus E
(P-value)
Barrett’s esophagus
(P-value)
A: herg1 expression evaluated through RT-PCR
Normal esophagus 0/6 (0%) / 0.317 0.118 0.008*
GERD 6/31 (19%) 0.317 / 0.166 0.002*
GERD plus E 13/40 (32%) 0.118 0.166 / 0.022*
Barrett’s esophagus 9/13 (69%) 0.008* 0.002* 0.022* /
B: hERG1 expression evaluated through IHC as reported in Materials and Methods
Normal esophagus 0/6 (0%) / 1.000 1.000 0.008*
GERD 0/31 (0%) 0.35 / 1.000 <0.0005*
GERD plus E 0/40 (0%) 1.000 1.000 / <0.0005*
Barrett’s esophagus 9/13 (69%) 0.008* <0.0005* <0.0005* /
Numbers in the first column of both tables represent the number of positive cases on the total number of samples. The percentage of positive cases is reported in
parentheses. Numbers in the other columns represent P-values obtained matching values referring to herg1 gene (A) and hERG1 protein (B) expression in the different
groups. Statistical analysis was performed through Fisher exact test.
*Statistically significant.
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and ADKs was limited to sparse cells, while hERG1
protein was present in almost all dysplastic/cancerous
epithelial cells.
Finally, we performed an IHC analysis on two cases
which were sampled and followed from BE to the cancer
stage, through D. IHC documentation of this evolution is
reported in Figure 2, part H. It is evident that hERG1
expression in BE metaplastic cells (part H1) is main-
tained also in dysplastic (part H2) as well as true cancer
cells (part H3).
Finally, BE samples where a 5-year or more follow-up
was available were analyzed. Samples were subdivided
into BE that did not proceed towards cancer (non-
progressed BE, npBE) and BE that progressed towards
adenocarcinoma (progressed BE, pBE) and the percen-
tage of hERG1 positive samples at the IHC analysis was
evaluated. It emerged (Fig. 4) that only 7% of the npBE
showed hERG1 protein expression. On the other hand,
almost all the pBE (89%) were hERG1 positive.
DISCUSSION
As far as we are aware, this article provides the first
evidence of hERG1 potassium channel expression in
physiologic and pathologic conditions of the human
upper gastrointestinal tract. In particular, present
findings show that hERG1 potassium channels are not
expressed in normal squamous esophageal mucosa.
Moreover, no hERG1 expression was detected in the
gastroesophageal junction mucosa collected below the
squamocolumnar junction, when the samples belonged
to normal patients, or to patients with inflammatory
conditions. On the contrary, hERG1 channels are
mis- and overexpressed in the metaplastic mucosa
present below the squamocolumnar junction that
characterizes BE.
The discovery of hERG1 potassium channels in BE
opens interesting biological perspectives. It has been
proposed that metaplastic cells characterizing BE
originate from a multipotential precursor cell present
in the esophagus itself (Mueller et al., 2004). herg1 may
belong to the class of genes that are expressed in
progenitor or true stem cells, to be actively transcribed
as these cells start to proliferate in response to either
growth factor/cytokine stimulation or neoplastic trans-
formation. This hypothesis is supported by the fact that
indeed hERG1 channels are expressed in stem cells
present in a cancer cell population, and mark a peculiar
stage of neoplastic cell differentiation (Biagiotti et al.,
2006). Moreover, the herg1 gene is not expressed in
resting peripheral blood CD34þ hematopoietic precur-
sors, but its transcription is switched on when CD34þ
cells start to proliferate in response to growth factors
and cytokines (Pillozzi et al., 2002). However, hERG1
expression does not configure just as a marker of
proliferating cells. In fact, hERG1 immunostaining does
not overlap with that of Ki67, a proliferation-related
antigen that has been previously reported to be
upregulated in BE and BE-derived ADKs (Fle´jou,
2005). In particular, the expression of hERG1 protein
in metaplastic cells characterizing BE is peculiar, since
all BE samples turned out to be negative for Ki67
expression. In addition, Ki67 positivity in Ds and ADKs
was limited to sparse cells, while hERG1 protein was
present in almost all dysplastic/cancerous epithelial
cells.
On the other hand, the herg1 gene could be envisaged
as a inflammation-related gene. In fact, we observed a
discrepancy between RT-PCR (Reverse transcription
and polymerase CHAIN reaction) and IHC data in E
samples. This could be apparently traced back to a
stronger presence of submucosal herg1 positive tissues
in those samples. Alternatively, a greater prevalence of
inflammatory cells in samples from this groups could be
responsible for the herg1 gene expression. The latter
hypothesis is confirmed by the fact that we indeed found
a significant presence of inflammatory cells (witnessed
by CD45 expression) in those endoscopic samples of the
GERD plus E group that turned out to be positive for
herg1 expression at the PCR analysis.
In other words, while herg1 is mainly expressed in
inflammatory cells in inflammatory lesions of the lower
esophagus, it is upregulated in epithelial cells in
metaplastic lesions. The increase in herg1 expression
in inflammatory cells could be related to a cytokine-
modulated effect of herg1 transcription. To confirm our
hypothesis, it has been recently reported that various
cytokines (IL-4, IL-5, IL-9, and IL-13) as well as TNF-a
can switch on cellular metaplasia in the airway
epithelium. This occurs through the activation of the
gene encoding a calcium-activated chloride conductance
(CLCA1) that in turn determines transcription of mucin
genes (Busse et al., 2005). The same role could be exerted
by hERG1 channels in the upper gastrointestinal tract,
and, hence, the hERG1 channel expression could be the
determinant factor in the switching on of cellular
metaplasia.
Another interesting result emerging from our data is
the finding that the hERG1 protein is highly expressed
in all the Ds as well as ADKs arising on a previously
diagnosed BE. This fact suggests the hypothesis
that herg1 gene expression marks an early step
along the progression of a normal cell toward a true
cancerous cell through a metaplastic and dysplastic
stage. Up to now, hERG1 channels have been found to
be overexpressed only in truly cancerous conditions
(Cherubini et al., 2000; Pillozzi et al., 2002; Smith
et al., 2002; Lastraioli et al., 2004; Masi et al., 2005),
while no hERG1 expression was detected in hyperpro-
liferative conditions, such as endometrial hyperplasias
or colorectal adenomas. In addition, hERG1 channels
turned out to be more frequently expressed in advanced
colorectal tumors. This may be due to the regulatory role
exerted by hERG1 channels on the modulation of cell
invasiveness (Lastraioli et al., 2004). In the upper gastro-
intestinal tract, this rule seems to be partially over-
whelmed, since herg1 expression is apparently switched
Fig. 4. hERG1 expression in BE samples in association with follow-
up. Histogram relative to IHC data obtained on archival samples.
Data are expressed as a percentage of the total number of samples
examined. npBE, non progressed Barrett’s esophagus (n¼ 14); pBE,
progressed BE (n¼ 9). White bars, hERG1 negative samples; Black
bars, hERG1 positive samples.
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on in an early stage of the neoplastic pathway, that is,
the metaplastic stage, to be further maintained through-
out tumor progression. This different behavior could be
related to different anatomical origin and the different
physiological function of the metaplastic, goblet cells,
that is, secretion. Indeed many types of Kþ channels,
including hERG1 channels (Ashcroft, 2000), regulate
cellular secretion in various types of cells. In addition, it
is worth recalling that the onset of the metaplastic
process in the upper gastrointestinal tract (esophagus,
stomach) always strictly depends upon chronic inflam-
mation. This process is apparently different from what
happens in colorectal carcinogenesis, and could explain
the early onset of aberrant expression of hERG1
channels. And in fact a similar early expression of
hERG1 channels also occurs in gastric cancer progres-
sion (Lastraioli et al., unpublished data).
Finally, our findings of hERG1 expression marking a
subset of patients whose BE lesion progressed to a true
adenocarcinoma may also have a clinical impact. In fact,
despite the limited number of patients examined, such
finding suggests the possibility that patients susceptible
to evolution to a true adenocarcinoma could be identified
on the basis of hERG1 expression.
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